1. P-263Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC). (20th June 2018) Authors: Avallone, A; Nasti, G; Rosati, G; Carlomagno, C; Romano, C; Bilancia, D; De Stefano, A; Silvestro, L; Ottaiano, A; Cassata, A; Bianco, F; Izzo, F; Delrio, P; De Gennaro, E; Casaretti, R; Tafuto, S; Albino, V; Pace, U; Lastoria, S; Gallo, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PD-015Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies. (2nd July 2019) Authors: Rossini, D; Sbrana, A; Bergamo, F; Manai, C; Santini, D; Ghidini, M; Antoniotti, C; Moretto, R; Marmorino, F; Urbano, F; Ronzoni, M; Noventa, S; Randon, G; Carlomagno, C; Latiano, T; Cordio, S; Granetto, C; Cremolini, C; Falcone, A; Antonuzzo, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗